SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced positive overall survival data from the ARTEMIS-008 Phase…

GSK plc · 6-K filed Sep 14, 2026 at 07:24 ET

At the news

BULLISHIMPACT 7/10

6-K filed Sep 14, 2026 at 07:24 ET

GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in relapsed small cell lung cancer in China. Ris-Rez reduced the risk of death by 54% vs topotecan (HR 0.46, p<0.0001), with median OS of 18.5 months vs 10.3 months, and showed a favorable safety profile. This is the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type, supporting GSK's global development program with pivotal data from the EMBOLD SCLC-301 trial expected next year.

  • Ris-Rez reduced risk of death by 54% vs topotecan in relapsed SCLC (HR 0.46; 95% CI: 0.35-0.62, p<0.0001)
  • Median OS: 18.5 months (Ris-Rez) vs 10.3 months (topotecan)
  • Median PFS: 7.2 months vs 3.0 months (HR 0.33)
  • Objective response rate: 58.3% vs 12.6%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access